Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Renflexis

- PMLiVE

Merck & Co halts development of potential COVID-19 drug MK-7110

Pharma company has abandoned drug due to technical, clinical and regulatory uncertainties

- PMLiVE

Keytruda plus chemotherapy gains US approval for advanced oesophageal cancer

First checkpoint inhibitor to win approval in the first-line setting for this cancer type

- PMLiVE

NICE rejects Keytruda for advanced bladder cancer in final guidance

Treatment had been authorised for use in this indication via the Cancer Drugs Fund in 2018

- PMLiVE

Merck & Co signs deal with Amathus for neurodegenerative diseases

Collaboration will focus on developing small molecules for undisclosed disease targets

- PMLiVE

Merck & Co, Ridgeback Biotherapeutics’ COVID-19 drug shows early promise

Molnupiravir led to a faster decrease in infectious virus among participants with early COVID-19

- PMLiVE

Merck & Co to help produce J&J’s COVID-19 vaccine in the US

Company has signed agreements to bolster vaccine manufacturing capacity

- PMLiVE

MSD withdraws Keytruda’s US indication for small cell lung cancer

Checkpoint inhibitor gained accelerated approval in 2019

- PMLiVE

Merck to acquire Pandion Therapeutics for $1.85bn

Merck will gain a pipeline of immune modulators targeting autoimmune diseases

- PMLiVE

AZ/Merck & Co’s PARP inhibitor Lynparza scores trial win in early breast cancer

Trial halted early after crossing superiority boundary for the primary endpoint of invasive disease-free survival

- PMLiVE

New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer

Data presented at the virtual American Society of Clinical Oncology’s Genitourinary Cancers Symposium

- PMLiVE

Merck’s CEO Kenneth Frazier to retire after ten years in the role

Frazier is handing the reins over to current Merck CFO Robert Davis

Roche Basel Switzerland

Roche’s diagnostic business sales offer a bright spot in Q4

Company's pharmaceutical division sales slipped due to biosimilar competition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links